Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics is a clinical-stage biopharmaceutical company advancing a portfolio of novel small-molecule and biologic drug candidates designed to address immuno-inflammatory and dermatologic conditions. The company’s approach centers on inhibiting specific protein kinases—particularly ITK (interleukin-2-inducible tyrosine kinase) and JAK3—to modulate immune responses that drive diseases like atopic dermatitis, psoriasis, and other inflammatory skin conditions.

The company’s lead oral candidate, ATI-2138 (a dual ITK/JAK3 inhibitor), has demonstrated clinical efficacy in moderate-to-severe atopic dermatitis patients in Phase 2a trials. Beyond oral inhibitors, Aclaris licensed a pipeline of biologic assets through agreements with Biosion, including bosakitug (anti-TSLP monoclonal antibody), positioning the company to pursue both small-molecule and biologic pathways across multiple inflammatory indications.

Operating with a strong balance sheet and runway extending into the latter half of 2026, Aclaris targets multiple clinical readouts across its programs. The company balances deep immunology expertise with the operational demands of advancing four clinical programs simultaneously, navigating the inherent execution risks of pre-commercial drug development while building a foundation for eventual commercialization.